Nasdaq

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of ...
Los Angeles Times

Cirrhosis Explained: Causes, Symptoms, and Treatment Paths

Cirrhosis is the result of long-term liver injury where healthy tissue is replaced with scar tissue (fibrosis). Common causes of cirrhosis include alcohol use disorder (AUD), nonalcoholic fatty liver ...
Medscape

AI Pathology Shows Efruxifermin Benefits in MASH, Cirrhosis

Efruxifermin significantly reduced both overall fibrosis and septal area in adults with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis, based on a post hoc analysis ...
Healio

Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Obeticholic acid failed to demonstrate ...
Business Insider

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage ...
Business Insider

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...